title: Correlation between 99mTc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy and pathological grading of meningioma.
abstract: The aim of this study was to explore the association of (99m)Tc-HYNIC-octreotide SPECT/CT somatostatin receptor scintigraphy (SRS) with the pathological grading and expression of somatostatin receptor 2 (SSTR2) for meningioma, and to define possible roles of SRS in the pathological grading of meningioma. Thirty patients with meningiomas diagnosed by MRI and treated with (99m)Tc-HYNIC-octreotide SPECT/CT SRS. Meningioma tissues were obtained from analyzing pathological grading and measuring the expression of SSTR2 with immunohistochemical staining. The meningioma side (T) to the contralateral side (NT) ratios (T/TN) of radioactive counts were calculated to investigate their association with the pathological grading of meningioma and the expression of SSTR2. All 30 cases showed high meningioma radioactivity accumulation using SRS with a sensitivity of 100 %, while CT scans only detected 25 cases with a sensitivity of 83 %. Twenty cases with grade I meningioma had a T/NT ratio of 3.80 ± 1.67, which was significantly lower than the other 10 cases (9.57 ± 3.78) with a grade II meningioma (P < 0.01). All meningiomas expressed SSTR2 as detected by immunohistochemical staining, and the T/NT ratio was positively associated with the pathological grading of meningioma and the expression of SSTR2 (with r of 0.784 and 0.805, respectively). (99m)Tc-HYNIC-octreotide SPECT/CT SRS is a sensitive technique for detecting meningioma, and the T/NT ratio of the SRS data closely correlates with the pathological grade of meningioma and the expression of SSTR2.
authors: Department of Nuclear Medicine, Xijing Hospital, Fourth Military Medical University, 15 West Changle Road, Xi'an, 710032 Shaanxi, China.
authors: Shengjun
authors: S
authors: Wang
authors: Weidong
authors: W
authors: Yang
authors: Jinglan
authors: J
authors: Deng
authors: Jianning
authors: J
authors: Zhang
authors: Fucheng
authors: F
authors: Ma
authors: Jing
authors: J
authors: Wang
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007091:Image Processing, Computer-Assisted; D007124:Immunoenzyme Techniques; D008279:Magnetic Resonance Imaging; D008297:Male; D008577:Meningeal Neoplasms / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D008579:Meningioma / Q000000981:diagnostic imaging / Q000378:metabolism / Q000473:pathology*; D008875:Middle Aged; D060787:Neoplasm Grading; D015282:Octreotide / Q000031:analogs & derivatives*; D015609:Organotechnetium Compounds; D011379:Prognosis; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin / Q000378:metabolism*; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed
chemical_list: D015609:Organotechnetium Compounds; D019275:Radiopharmaceuticals; D017481:Receptors, Somatostatin; C574734:SSTR2 protein, human; C410263:technetium Tc 99m hydrazinonicotinyl-Tyr(3)-octreotide; D015282:Octreotide
references: Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):48-52
references: 18807033
references: J Nucl Med. 2000 Jun;41(6):1114-9
references: 10855644
references: J Nucl Med. 2003 Nov;44(11):1767-74
references: 14602858
references: Clin Neuropathol. 2008 Sep-Oct;27(5):334-45
references: 18808065
references: Semin Nucl Med. 2002 Apr;32(2):84-91
references: 11965603
references: Eur J Nucl Med Mol Imaging. 2005 Dec;32(12):1440-51
references: 16133384
references: Mod Pathol. 2007 Nov;20(11):1172-82
references: 17873898
references: J Nucl Med. 1995 Mar;36(3):403-10
references: 7884502
references: J Neurooncol. 2004 Nov;70(2):183-202
references: 15674477
references: Breast Cancer Res Treat. 2002 Apr;72(3):221-6
references: 12058963
references: J Neurooncol. 2007 Jan;81(2):167-74
references: 16850106
references: Eur J Nucl Med. 1998 Jul;25(7):675-86
references: 9662588
references: Neuropathol Appl Neurobiol. 2005 Apr;31(2):141-9
references: 15771707
references: Int J Cancer. 1998 May 29;76(5):620-7
references: 9610716
references: J Neurooncol. 2004 Jan;66(1-2):155-66
references: 15015781
references: J Nucl Med. 1998 Nov;39(11):1913-7
references: 9829583
references: J Neurosurg. 2012 Dec;117(6):999-1006
references: 23061394
references: Int J Radiat Oncol Biol Phys. 2006 May 1;65(1):222-7
references: 16488553
references: Eur J Nucl Med. 2001 Jul;28(7):836-46
references: 11504080
references: Oncol Rep. 2005 Jan;13(1):31-5
references: 15583798
references: J Nucl Med. 2005 May;46(5):763-9
references: 15872348
references: Surg Neurol. 1986 Mar;25(3):233-42
references: 3945904
references: Clin Cancer Res. 2000 May;6(5):1865-74
references: 10815909
references: Acta Neurochir (Wien). 2005 Apr;147(4):367-74; discussion 374-5
references: 15696264